Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans

Xenobiotica

Volumn 43, Issue 5, 2013, Pages 432-442

  Furuta, Shinji ^a   Smart, Clair ^b   Hackett, Andrew ^b   Benning, Rajdeep ^c   Warrington, Steve ^c  

^a SANWA KAGAKU KENKYUSHO CO LTD   (Japan)

^b Huntingdon Life Sciences ^*  (United Kingdom)

^c Hammersmith Medicines Research Limited and Trio Medicines Limited   (United Kingdom)

Author keywords

Anagliptin; DPP 4 inhibitor; Excretion; Human; Metabolism; Pharmacokinetics

Indexed keywords

ANAGLIPTIN; BREAST CANCER RESISTANCE PROTEIN; CARBON 14; DRUG METABOLITE; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; OCTAMER TRANSCRIPTION FACTOR 2; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; SKL 12277; SKL 12320; UNCLASSIFIED DRUG; CARBON; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PYRIMIDINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; FECES ANALYSIS; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; RADIOACTIVITY; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; ADULT; BLOOD; HALF LIFE TIME;

ADULT; CARBON RADIOISOTOPES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HALF-LIFE; HUMANS; MALE; PYRIMIDINES;

EID: 84875859488     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.731618     Document Type: Article

References (37)

1. Ahren B. (2009). Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. Best Pract Res Clin Endocrinol Metab 23: 487-498.
2. Atack JR, Yu QS, Soncrant TT, Brossi A, Rapoport SI. (1989). Comparative inhibitory effects of various physostigmine analogs against acetyland butyrylcholinesterases. J Pharmacol Exp Ther 249: 194-202. (Pubitemid 19115808)
3. Brandt I, Joossens J, Chen X, Maes MB, Scharpe S, De Meester I, Lambeir AM. (2005). Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl) amino]acetyl}-pyrrolidine-2- carbonitrile). Biochem Pharmacol 70: 134-143. (Pubitemid 40797877)
4. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. (2001). Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol 59: 1277-1286. (Pubitemid 32385197)
5. Chen ZS, Lee K, Kruh GD. (2001). Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 276: 33747-33754.
6. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. (1995a). Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2- terminus in type II diabetic patients and in healthy subjects. Diabetes 44: 1126-1131.
7. Deacon CF, Johnsen AH, Holst JJ. (1995b). Degradation of glucagonlike peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80: 952-957.
8. Drucker DJ, Nauck MA. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705. (Pubitemid 46048557)
9. Duez H, Cariou B, Staels B. (2012). DPP-4 inhibitors in the treatment of type 2 diabetes. Biochem Pharmacol 83: 823-832.
10. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L; International Transporter Consortium. (2010). Membrane transporters in drug development. Nat Rev Drug Discov 9: 215-236.
11. Halimi S, Schweizer A, Minic B, Foley J, Dejager S. (2008). Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet. Vasc Health Risk Manag 4: 481-492. (Pubitemid 352037910)
12. Hatfield MJ, Tsurkan L, Garrett M, Shaver TM, Hyatt JL, Edwards CC, Hicks LD, Potter PM. (2011). Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Biochem Pharmacol 81: 24-31.
13. Hirohashi T, Suzuki H, Chu XY, Tamai I, Tsuji A, Sugiyama Y. (2000). Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2). J Pharmacol Exp Ther 292: 265-270. (Pubitemid 30026380)
14. Idris I, Donnelly R. (2007). Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. Diabetes Obes Metab 9: 153-165. (Pubitemid 46206559)
15. Islinger F, Gekle M, Wright SH. (2001). Interaction of 2,3-dimercapto- 1-propane sulfonate with the human organic anion transporter hOAT1. J Pharmacol Exp Ther 299: 741-747.
16. Jbilo O, Bartels CF, Chatonnet A, Toutant JP, Lockridge O. (1994). Tissue distribution of human acetylcholinesterase and butyrylcholinesterase messenger RNA. Toxicon 32: 1445-1457. (Pubitemid 24345350)
17. Kato N, Oka M, Murase T, Yoshida M, Sakairi M, Yamashita S, Yasuda Y, Yoshikawa A, Hayashi Y, Makino M, Takeda M, Mirensha Y, Kakigami T. (2011). Discovery and pharmacological characterization of N-[2-({2-[(2S)-2- cyanopyrrolidin-1-yl]-2- oxoethyl}amino)-2-methylpropyl]-2-methylpyrazolo[1,5-a] pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor. Bioorg Med Chem 19: 7221-7227.
18. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. (2005). Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 20: 379-386.
19. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S. (1989). Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38: 902-905. (Pubitemid 20022397)
20. Lambeir AM, Durinx C, Scharpe S, De Meester I. (2003). Dipeptidylpeptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: 209-294. (Pubitemid 36775376)
21. Masaki K, Hashimoto M, Imai T. (2007). Intestinal first-pass metabolism via carboxylesterase in rat jejunum and ileum. Drug Metab Dispos 35: 1089-1095. (Pubitemid 46956428)
22. Mentlein R, Gallwitz B, Schmidt WE. (1993). Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214: 829-835. (Pubitemid 23188160)
23. Mest HJ, Mentlein R. (2005). Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 48: 616-620. (Pubitemid 40591214)
24. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. (1986). Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 63: 492-498. (Pubitemid 16035703)
25. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307. (Pubitemid 23037285)
26. Orskov C, Holst JJ, Nielsen OV. (1988). Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013.
27. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. (2004). Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 141: 929-937.
28. Scheen AJ. (2003). Current management strategies for coexisting diabetes mellitus and obesity. Drugs 63: 1165-1184. (Pubitemid 36750949)
29. Sharma MD. (2010). Role of saxagliptin as monotherapy or adjunct therapy in the treatment of type 2 diabetes. Ther Clin Risk Manag 6: 233-237.
30. Shaw JE, Sicree RA, Zimmet PZ. (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
31. Stumvoll M, Goldstein BJ, van Haeften TW. (2005). Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365: 1333-1346.
32. Sunami Y, Yoshioka N, Hayashi I, Ishida T. (2007). Safety, tolerability, pharmacokinetics and pharmacodynamics of sk-0403, a novel dpp-iv inhibitor, in healthy japanese subjects. American Diabetes Association 67th Scientific Session, Chicago, IL, Jun. 22-26, Poster 0482-P [Online]. Available at: http://professional.diabetes.org/Content/Posters/2007/p0482-P.pdf (Accessed on 13 September 2012).
33. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. (1992). Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263: 840-845.
34. Vilsboll T, Agerso H, Krarup T, Holst JJ. (2003). Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 88: 220-224. (Pubitemid 36115169)
35. Volk EL, Schneider E. (2003). Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 63: 5538-5543. (Pubitemid 37139875)
36. Wahlby S, Engstrom L. (1968). Studies on Streptomyces griseus protease. II. The amino acid sequence around the reactive serine residue of DFP-sensitive components with esterase activity. Biochim Biophys Acta 151: 402-408.
37. Zerilli T, Pyon EY. (2007). Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. Clin Ther 29: 2614-2634.